Chronic inflammation, wound healing and granulomas

Inflammation is the response of living, vascularised tissue to injury, infection or material that the body recognises as harmful. It brings defensive cells and soluble signals to the affected area, helps remove the cause of injury and begins repair. Acute inflammation is usually relatively rapid and short-lived. Chronic inflammation persists when the stimulus remains or the response is not adequately resolved. In chronic inflammation, ongoing tissue injury and attempts at repair occur together, so the same response that protects the body can also damage its own tissues.

A characteristic tissue pattern is the presence of macrophages, lymphocytes and other mononuclear cells, alongside damaged tissue and signs of repair such as new vessels or fibrosis. The balance varies with the cause and site. A granuloma is a more organised pattern: activated macrophages gather into a compact focus, often becoming epithelioid cells, with multinucleated giant cells and lymphocytes nearby. It is an attempt to contain material that is difficult to eliminate, such as certain persistent microbes or foreign substances. Granulomas can help limit spread, but the surrounding inflammation and fibrosis may impair normal tissue function. Their appearance alone does not identify the cause; clinical context and, when needed, tissue sampling are important.

Wound healing is the restoration of tissue continuity after injury. It involves inflammation, cell growth and matrix formation, followed by reorganisation of the repaired area. These activities overlap rather than switching on and off as isolated events. A wound may fail to progress if its cause continues, its local environment remains unfavourable, or inflammation stays excessive. Many chronic wounds become stuck in the inflammatory phase, preventing progress towards healing^[1].

A useful way to organise wound-bed assessment is the TIME framework: Tissue assessment and management, Infection/Inflammation management, Moisture imbalance/management, and Edge of wound observation and management^[1]. This framework helps structure attention to the wound and its surroundings; it is not a guarantee that healing will follow, since some wounds fail to heal even when these principles are applied^[1]. The condition of the wound, its location, exudate, surrounding skin and whether it is infected or stalled in inflammation all influence dressing choice^[1].

Macrophages are central to chronic inflammation. They arise from circulating monocytes that enter tissue, and they can also be maintained by local tissue populations. Macrophages ingest microbes, dead cells and debris. They release cytokines and chemokines that recruit or activate other cells, and growth factors that influence blood vessels, fibroblasts and epithelial cells. Their behaviour is adaptable: signals from microbes and damaged tissue can sustain inflammatory activity, while signals associated with resolution and repair can shift their functions. These are overlapping states, not fixed cell types.

Lymphocytes help shape and sustain the response. T cells recognise specific antigens and can direct macrophage activity or coordinate other immune cells through cytokines. Some T-cell responses favour cellular defence; others restrain inflammation or support tissue repair. B cells can become antibody-secreting plasma cells, adding a targeted response to the local process. In a granuloma, lymphocytes often collect around activated macrophages, helping maintain and regulate the organised focus. ^[1]

Neutrophils are prominent in many acute responses, but may also continue to enter a chronically inflamed wound. They kill microbes and release enzymes and reactive molecules that break down damaged material. If these substances persist in excess, they can also injure viable tissue and degrade the matrix needed for repair. Mast cells, endothelial cells and fibroblasts contribute signals of their own: they influence vascular permeability, cell recruitment, new vessel formation and matrix production.

The activity of these cells is coordinated by mediators. Cytokines regulate activation and communication; chemokines guide cell movement; growth factors influence cell survival, proliferation and tissue construction. Lipid mediators and complement products can promote vascular changes and recruit defensive cells. Proteases, including matrix metalloproteinases, digest extracellular matrix and other proteins. Their activity must be balanced by inhibitors so that damaged material can be cleared without excessive destruction of healthy tissue.

In chronic ulcers, pathologically extensive inflammation can contribute to delayed healing. A hostile wound microenvironment may contain excess inflammatory cells and a disrupted balance between pro-inflammatory mediators, such as chemokines, cytokines and proteases, and their inhibitors^[1]. This helps explain why inflammation is not simply helpful or harmful: its effect depends on its intensity, duration and regulation. The extracellular matrix is also an active part of this communication. Interactions between cells and matrix can activate biochemical mediators, cytokines and growth factors that influence wound physiology^[1].

The inflammatory phase begins as the wound is sealed and the body limits blood loss and contamination. A clot provides temporary cover and a scaffold for incoming cells. Local vessels become more permeable, allowing immune cells and soluble proteins to reach the injured area. Neutrophils help clear microbes and debris; monocytes enter and develop into macrophages, which continue clearance while coordinating the transition towards repair. Inflammation is useful when it is controlled and resolves as the wound bed becomes ready for rebuilding. Persistent contamination, repeated injury or dysregulated inflammatory signals can keep the wound in this phase and obstruct progress^[1].

The proliferative phase builds replacement tissue. Fibroblasts move into the wound and produce extracellular matrix, creating a supportive bed for cells and new vessels. Endothelial cells form capillaries that supply oxygen and nutrients to the growing tissue. The resulting vascular, matrix-rich tissue is called granulation tissue; its name describes its appearance, not a granuloma. Keratinocytes at the wound edge migrate over the surface to restore the skin barrier. Some fibroblasts acquire contractile properties and draw the wound edges towards one another. These processes depend on signals from inflammatory cells and on a matrix that can support cell attachment and movement.

During remodelling, the provisional matrix is reorganised into a more durable scar. Collagen is deposited, broken down and rearranged; proteases and their inhibitors help regulate this turnover. Excess vessels regress as the tissue becomes less active, and contractile cells diminish. The scar becomes more organised but does not reproduce all the structure or function of uninjured tissue. Remodelling can continue after the surface has closed, and the result depends on the quality of the earlier repair as well as ongoing strain or inflammation.

The phases overlap, and the wound environment can help or hinder their progress. Excess exudate, infection, surrounding-skin damage or persistent inflammatory activity may disrupt the wound bed and delay repair. The TIME framework draws attention to tissue, infection or inflammation, moisture and wound edges when assessing these issues^[1]. Modern dressings may provide or maintain a moist environment^[1], while their selection depends on wound features including exudate, location and whether healing is stalled^[1]. Collagen can support fibroblast chemotaxis, wound contraction and growth-factor and cytokine activity; it also interacts with matrix metalloproteinases^[1]. Collagen-based dressings are used to mimic aspects of the native wound microenvironment^[1]. These materials can support the repair environment, but they do not remove the need to address the underlying cause of a wound.

Granulomatous inflammation is a way the immune system contains material that it cannot readily remove. It is a pattern of chronic inflammation, not a diagnosis in itself. At its centre are activated macrophages, often called epithelioid cells because they become enlarged and closely grouped. Some macrophages fuse into multinucleated giant cells. Lymphocytes commonly surround these cells, and persistent inflammation can lead to fibrosis around the granuloma.

A granuloma may form when a persistent infectious agent resists destruction or clearance. Tuberculosis is a familiar bacterial example; leprosy and some fungal infections can also produce granulomas. Certain parasites may provoke a similar response, particularly when the immune system reacts to material that remains in tissue. The organism and the host response both influence the appearance of the lesion. Some granulomas have central necrosis, while others do not. Necrosis can suggest particular causes in the right context, but its presence or absence does not, by itself, establish the cause.

Granulomas can also arise without an active infection. In some immune-mediated diseases, the inflammatory response is directed at the body’s own tissues or at an exposure that provokes a persistent cellular reaction. Sarcoidosis is an important example; granulomas may affect several organs, and the cause is not fully understood. Crohn’s disease can also be associated with granulomatous inflammation. Chronic exposure to certain substances, including beryllium, can produce a granulomatous response and may resemble sarcoidosis.

A further cause is foreign material that is too large, durable or chemically resistant for ordinary phagocytosis to clear. Examples include splinters, suture material and other implanted particles. Macrophages gather at the material and may fuse around it, forming a foreign-body-type giant cell. In this setting, the granuloma is an attempt to wall off the irritant. The reaction can persist for as long as the material remains in the tissue.

The microscopic pattern helps explain the process but does not always identify its cause. Giant-cell shape and arrangement can vary, and they are not reliable in isolation as a way to name a particular disease. A caseating appearance may raise suspicion of infection, but other causes can produce necrosis too. Likewise, a non-necrotising granuloma does not prove a non-infectious cause. The clinical setting matters: symptoms, affected organ, immune status, occupational and other exposures, and the possibility of infection all help interpret the tissue findings.

Understanding the cause matters because the same inflammatory pattern can arise through different mechanisms. A persistent organism calls for a different response from retained foreign material or an immune-mediated disease. Treating the visible inflammation without addressing its driver may leave the process active. Granulomas therefore illustrate a general principle of chronic inflammation: containment can limit immediate spread, but a response that cannot resolve may itself damage the surrounding tissue.

A scar forms as the body repairs a wound. In ordinary healing, inflammatory cells clear damaged tissue, new blood vessels support repair, and fibroblasts produce collagen to provide strength. As the wound matures, collagen is reorganised and some of the excess matrix is removed. If collagen production and breakdown remain out of balance, the repair tissue can become raised and thickened.

A hypertrophic scar is raised but remains within the boundary of the original wound. It may be red, firm, itchy or tender, particularly while it is active. Its bulk reflects excess repair tissue rather than a separate mass. Over time, a hypertrophic scar may become flatter and less symptomatic as the tissue remodels. Wound tension, prolonged inflammation and delayed closure can contribute to excessive scarring, although the appearance of a scar reflects several interacting factors rather than a single cause.

A keloid grows beyond the original wound boundary into nearby skin. It may continue enlarging after the wound has closed and may not regress in the same way as a hypertrophic scar. It can be itchy, painful or sensitive, and may recur after being removed because the tendency to produce excess scar tissue remains. A small injury, such as a piercing or an acne lesion, can be followed by a keloid; the size of the visible scar need not match the apparent severity of the original injury.

The boundary of the original injury is the clearest practical distinction: hypertrophic scarring stays within it, whereas a keloid extends beyond it. Timing and behaviour can help too. A hypertrophic scar often develops during wound repair and may settle as it matures; a keloid can persist or expand beyond the period of ordinary wound healing. These patterns are useful descriptions, not substitutes for considering the history and examination. Raised scars can be difficult to classify when the original injury is unclear or when the lesion is still changing.

Microscopically, both patterns involve excess collagen and other extracellular matrix. Their tissue architecture can differ, but appearance under the microscope is interpreted alongside the clinical course and the scar’s relation to the wound. Neither should be confused with a wound that remains open: a raised scar is repaired tissue, while an unhealed wound indicates that closure has not been achieved. Persistent inflammation or infection may complicate healing and contribute to abnormal repair.

The distinction matters because the likely course differs. A hypertrophic scar may gradually soften and flatten, while a keloid can remain active beyond the wound edges. In either case, symptoms, movement restriction and the person’s concerns are relevant when planning care. Preventing repeated injury and reducing unnecessary tension on a healing wound are general aims of good repair; treatment choices depend on the individual scar and clinical context.

Clinical data for Integra describe collagen deposition histologically indistinguishable from native dermal collagen, with good-quality tissue and no hypertrophic or keloid scar formation. This finding concerns that wound-healing material; it does not mean that all wounds heal without abnormal scarring or that the two scar patterns are interchangeable. ^[1]

Chronic inflammation occurs when the cause of tissue injury persists or the response fails to switch off. It may protect the body by containing infection or removing persistent material, but the same immune activity can damage surrounding tissue. Repair then proceeds alongside injury: fibroblasts lay down extracellular matrix, new vessels support the tissue, and collagen can accumulate as fibrosis. A granuloma is one organised form of chronic inflammation, in which macrophages gather around material they cannot readily remove.

Granulomas are seen in infections such as tuberculosis and some fungal diseases, in immune-mediated conditions such as sarcoidosis and Crohn’s disease, and around foreign material. They can help contain a persistent stimulus, but may also distort or destroy normal tissue. In Crohn’s disease, granulomatous inflammation can occur in the bowel wall; in sarcoidosis, granulomas may affect organs such as the lungs. These examples illustrate why finding a granuloma describes a tissue response, not its cause: the underlying condition still needs to be identified.

Wound healing depends on inflammation being timely and proportionate. Early inflammatory cells clear microbes and damaged tissue; macrophages and other signals then support new blood vessels, fibroblast activity and matrix formation. If inflammation persists, a wound may remain open, with continuing tissue damage and poor repair. Chronic wounds have been associated with high levels of pro-inflammatory cytokines. In wound repair, epithelial cells can also undergo epithelial–mesenchymal transition: they lose some cell-to-cell connections and acquire features associated with fibroblasts, including expression of fibronectin and α-smooth muscle actin.

These mechanisms have clinical relevance to dressings and tissue repair. A collagen/ORC dressing can bind platelet-derived growth factor and protect it from degradation in the wound. In scaffold research, a collagen-based construct carrying VEGF and SDF-1α was associated with fewer pro-inflammatory M1 macrophages and greater blood-vessel formation. A separate modified-collagen dressing study reported a decreased pro-inflammatory ‘M1’ phenotype and promoted an ‘M2’ phenotype. These experimental findings support investigation of ways to encourage repair, but do not by themselves establish how well a dressing will work in patients. ^[1]

Chronic inflammation can also be associated with malignancy. Primary sclerosing cholangitis (PSC) causes inflammation and fibrosis of the bile ducts, which can narrow them. The reported cumulative lifetime incidence of cholangiocarcinoma in PSC is around 20%. More than 50% of patients with PSC develop cholangiocarcinoma simultaneously or within 1 year of diagnosis. Reported incidence after PSC diagnosis is around 0.5–1.5% per year. New jaundice in a patient with PSC is a reason to suspect cholangiocarcinoma. ^[2]

Investigation starts by connecting the tissue pattern to the patient’s symptoms and history. For a wound, assess its site, appearance, depth, drainage, surrounding skin and evidence of healing or ongoing tissue damage. Ask about factors that could impair repair, such as poor blood supply, pressure, diabetes, smoking, infection or repeated trauma. Blood tests can support assessment of systemic inflammation or infection: a full blood count may show changes in white cells, while C-reactive protein and erythrocyte sedimentation rate can reflect inflammation. These tests are not specific; a raised result does not identify the cause or prove that a wound is infected.

When infection is suspected, samples should be chosen to answer a clinical question. A swab from a superficial wound may reflect colonising organisms rather than the cause of deeper disease. Tissue or fluid collected from the affected area can be more informative when deeper infection is considered. Culture can identify organisms and help determine antimicrobial susceptibility. If tuberculosis or fungal infection is possible, request appropriate microscopy, stains, culture or molecular testing; a negative result from one method does not necessarily exclude infection.

Biopsy is important when the appearance or course of a lesion raises concern for granulomatous disease, malignancy or an unusual infection. Histology can show collections of epithelioid macrophages, multinucleated giant cells and surrounding inflammatory cells. The presence or absence of necrosis can help characterise the pattern, but is not sufficient on its own to establish the cause. The pathologist should be given the clinical context and suspected causes so that appropriate stains and further tests can be considered. Where a granuloma is found, investigations should distinguish infection, immune-mediated disease and a reaction to foreign material.

For suspected systemic disease, combine laboratory findings with organ-specific assessment. In a patient with possible sarcoidosis, for example, interpret tissue findings alongside respiratory symptoms, examination and imaging rather than treating a blood marker as diagnostic in isolation. In suspected inflammatory bowel disease, stool and blood tests can indicate inflammation or complications, while endoscopy and biopsy help assess the bowel directly. In PSC, liver biochemistry can suggest biliary injury; imaging and, where appropriate, tissue assessment help clarify the cause of abnormal results and investigate a new change such as jaundice.

Laboratory studies can also be used to examine wound biology, not just diagnose disease. Researchers may assess inflammatory-cell types, cytokine expression, vessel formation and tissue oxygenation to understand whether a treatment is shifting the local environment towards repair. A modified-collagen dressing was examined in a mouse model for inflammation after 3 and 7 days. Such measurements help explain biological effects, but findings from an experimental model should not be treated as proof of benefit in human wounds. ^[1]

Chronic inflammation persists when the stimulus is not cleared or when immune activity continues to cause tissue injury. Repair may proceed at the same time: fibroblasts lay down connective tissue, new vessels form, and damaged tissue is remodelled. If injury and repair remain out of balance, the result can be a non-healing wound, excessive scarring, or loss of normal tissue function. A granuloma is one organised form of chronic inflammation. Activated macrophages gather around material they cannot readily remove, sometimes with lymphocytes and surrounding fibrous tissue. This arrangement helps contain the stimulus, but can also damage or distort the affected organ.

Treatment is guided by the cause and the tissue problem, rather than by the appearance of inflammation alone. Antimicrobials act against susceptible infectious causes; they do not remove a non-infectious trigger. Glucocorticoids reduce inflammatory signalling and immune-cell activity, while other immunomodulating medicines can block particular immune pathways. These approaches may be useful in inflammatory disease, but suppressing inflammation can also weaken infection control and slow wound repair. Non-steroidal anti-inflammatory medicines reduce prostaglandin production and can relieve pain, but symptom relief does not itself remove the cause of a persistent wound or granuloma. Drug choice therefore requires attention to infection, tissue damage, healing, and the underlying disease.

Wound care also acts directly on the local environment. Dressings can protect the wound, manage moisture, and support repair; they do not substitute for addressing factors that keep tissue injured. Bio-derived dressings aim to resemble parts of the native extracellular matrix. One example combines collagen and oxidised regenerated cellulose: the Promogran Matrix contains 55% type I bovine collagen and 45% oxidised regenerated cellulose. A related Promogran Prisma Matrix replaces 1% of the oxidised regenerated cellulose with silver-ORC, giving it antimicrobial properties. These are examples of product composition, not proof that one dressing suits every wound. ^[1]

Synthetic dressings can be manufactured reproducibly and tailored, but may be more inert than bio-derived materials. They may provide less of a physiological environment for repair, and their breakdown products need consideration. UrgoStart uses a polyester mesh with a lipido-colloid matrix containing sucrose octasulfate potassium salt, also called NOSF. The matrix forms a colloidal solution that conforms to the wound bed; NOSF has been shown to reduce matrix metalloproteinase levels and help restore growth-factor activity, while the matrix maintains a moist environment. Clinical studies report effectiveness in diabetic, venous, and pressure ulcers, although the mechanism is not fully established.

A QHREDGS-functionalised hydrogel has shown promise in laboratory work: it improved keratinocyte resistance to oxidative stress and shifted macrophage cytokine expression towards both pro- and anti-inflammatory signals. That suggests a possible way to influence a stalled wound response, not an established treatment for patients. With many dressings making similar claims, practitioners need to weigh the wound’s needs, the evidence for the product, and the broader treatment plan.

The same inflammatory process can have different consequences depending on the person and the site. In diabetes, oxidative stress can affect skin cells and chronic wounds may remain stalled in inflammation. The QHREDGS hydrogel findings are relevant to this problem, but they are laboratory findings rather than evidence of proven clinical benefit. Diabetes can also coexist with impaired sensation or circulation, so a wound may be noticed late or heal poorly. Care needs to consider the person’s overall health and the factors sustaining tissue injury, not just the visible wound surface.

Venous ulcers, pressure ulcers, and diabetic ulcers have different underlying stresses. Venous disease can sustain tissue swelling and injury; prolonged pressure can reduce local tissue perfusion; and diabetes can impair normal repair. UrgoStart has been studied in these ulcer groups, but that does not establish that it is appropriate for every patient or every wound. Product selection should account for the cause, wound bed, infection risk, moisture, comfort, and the person’s capacity to follow a care plan. Frailty, immobility, sensory impairment, and other chronic illnesses can alter both treatment priorities and the practical work of wound care.

Granulomas also occur in varied settings. Some form in response to persistent infection, while others arise around foreign material or in immune-mediated disease. The appearance of a granuloma alone does not identify its cause. Treatment therefore depends on finding and addressing the underlying trigger; reducing immune activity without considering infection can be harmful. In people with impaired immune function, both persistent infection and unusual inflammatory responses may be important possibilities. Decisions about immune-suppressing drugs need to balance control of tissue-damaging inflammation against the ability to contain infection.

A global approach must account for differences in access to diagnosis, medicines, dressings, trained wound care, and follow-up. A sophisticated dressing is only useful if it can be supplied consistently and used correctly. Where resources are limited, clear assessment of the cause, basic wound protection, infection recognition, and continuity of care remain important. Conversely, having a wide product range does not make selection straightforward: dressings can have different compositions but similar claims. Clinicians should distinguish a plausible mechanism from demonstrated benefit, and laboratory findings from evidence in patients.

Care also needs to fit the person’s circumstances. Mobility, nutrition, pain, available support, and the ability to keep a wound protected can all shape healing and the feasibility of treatment. Communication should explain what a dressing can and cannot do, why the underlying cause matters, and when reassessment is needed. These principles apply across settings: match treatment to the disease process, avoid assuming all chronic inflammation is the same, and judge wound products in the context of the individual rather than by marketing claims alone.

Inflammation is the tissue response to infection or injury. It brings cells and soluble signals to the affected site, with the aim of removing the cause of disturbance and supporting repair. If the threat is cleared and tissue repair succeeds, the response can resolve and the tissue can return towards homeostasis. Chronic inflammation describes a response that persists because the trigger remains, tissue damage continues, or regulation and resolution are inadequate. It is not simply a longer version of acute inflammation: ongoing injury and repair can occur side by side.

Macrophages are central coordinators. They ingest microbes and damaged material, release signals that recruit or activate other cells, and influence whether tissue is remodelled or replaced by scar. Lymphocytes can sustain inflammation by directing macrophage activity, while macrophages can shape the adaptive response in return. The balance of these signals matters: an effective response contains damage and enables repair; a poorly resolved response can perpetuate injury.

A granuloma is an organised collection of activated macrophages, often with a surrounding rim of lymphocytes. Some macrophages become large epithelioid cells; others fuse to form multinucleated giant cells. This arrangement helps wall off material that is difficult to eliminate. It may contain an infectious agent, persistent foreign material, or a stimulus whose cause is not apparent. A granuloma is therefore a pattern of inflammation, not a diagnosis by itself.

Wound healing depends on both cells and the extracellular matrix (ECM), the framework in which cells sit and move. In skin, the epidermal basement membrane separates epidermis from dermis, while dermal ECM includes fibroblasts, connective-tissue fibres, adhesion proteins, glycosaminoglycans and proteoglycans. Collagen is the major component of dermal ECM, accounting for ∼70% of skin (dry weight). The skin contains 28 genetically different collagen variants, with types I and III the most abundant. Fibroblasts make and remodel this matrix; its organisation helps determine tissue strength and the quality of the healed wound. ^[1]

Healing is best understood as overlapping activity rather than a rigid sequence. A clot provides temporary support; inflammatory cells remove contaminants and damaged tissue; new vessels and connective tissue develop; and the matrix is remodelled. The final tissue may restore much of its structure, or remain as a scar when the original architecture cannot be recreated. Inflammation is useful during this process, but it must be brought under control.

A common mistake is to treat all chronic inflammation as granulomatous. Chronic inflammation may instead show a diffuse mixture of macrophages, lymphocytes, plasma cells, tissue injury and repair. A granuloma is a more organised structure within that broader category. Conversely, finding a granuloma does not prove a particular infection: similar architecture can arise around foreign material or in immune-mediated disease. The microscopic pattern must be interpreted alongside the clinical story, tissue site and relevant investigations.

Do not assume that inflammation and healing are opposites. Inflammatory cells can clear damaged tissue and provide signals that recruit cells needed for repair. The problem is not inflammation itself, but an excessive, misdirected or persistent response. If the trigger remains, tissue damage may continue while repair deposits matrix. That combination can distort normal architecture and promote fibrosis. If the trigger is removed and the response resolves, repair may proceed without the same continuing injury.

Another trap is to equate wound closure with complete restoration. A surface may close while deeper tissue remains disorganised or weak. Repair by scar restores continuity, but does not necessarily recreate the original arrangement of specialised cells and matrix. The outcome depends on the extent of damage, the tissue’s capacity to regenerate, local blood supply, infection and the persistence of the insult. Avoid assuming every healed wound has returned to its prior function.

Persistent inflammation can also damage tissues through reactive oxygen and nitrogen species. These molecules can cause oxidative stress and injure lipids, proteins and DNA. The DNA damage marker 8-oxo-7, 8-dihydro-2′-deoxyguanosine (8-oxodG) is used to indicate such damage. The described damage can contribute to a G:C to T:A transversion. Chronic inflammatory settings in which such markers have been identified include Helicobacter pylori-associated gastritis, hepatitis and ulcerative colitis. This is a possible link between sustained injury and carcinogenesis, not a claim that chronic inflammation inevitably causes cancer. ^[2]

Finally, do not over-read the presence or absence of necrosis. A granuloma with central necrosis may suggest some causes more than others, but necrosis is not a stand-alone verdict; non-necrotising granulomas are not exclusive to one disease either. Sampling can miss a focal feature, and prior treatment or the stage of disease can alter appearances. Describe what the tissue shows before inferring why it is there.

These concepts help connect a biopsy appearance to the patient’s disease process. When a specimen shows chronic inflammation, ask what is maintaining it: an infection, a foreign body, an immune response, repeated tissue injury or an unresolved cause. Then assess what the inflammation is doing to the tissue. Is it damaging specialised structures, forming granulomas, producing fibrosis, or accompanying repair? That distinction helps organise the differential diagnosis without treating one microscopic feature as conclusive.

When a granuloma is reported, consider whether it is necrotising or non-necrotising, whether giant cells or foreign material are visible, and what other tissue changes accompany it. These observations guide further reasoning, but they do not replace microbiological testing, imaging or clinical assessment. For instance, a granuloma in a patient with relevant exposure and compatible symptoms raises different questions from one found around material introduced by a procedure. The appearance must be interpreted in context.

The same framework is useful in wound assessment. Delayed closure, persistent discharge, tissue breakdown or a firm scar may reflect different problems: ongoing contamination, impaired perfusion, continued mechanical stress, excessive inflammation or abnormal matrix remodelling. Looking at the wound’s edges alone can miss deeper injury. The ECM provides both support and signals for cell movement, so disruption of that scaffold can affect how cells migrate and how new tissue is organised. In skin, collagen is a major part of the dermal framework.

Chronic inflammation also matters beyond the local lesion. A prolonged inflammatory environment can expose neighbouring cells to repeated injury and repair signals. Oxidative damage is one proposed link between chronic inflammation and cancer-related changes; the marker 8-oxodG is used to identify DNA damage. This connection helps explain why a clinician may investigate persistent inflammation carefully, but does not make inflammation a cancer diagnosis. The clinical question remains whether there is evidence of an underlying cause or complication.

A practical teaching outline is to move from the observed pattern to the likely process, then check the proposed cause against independent evidence. It is not a protocol: the appropriate investigation depends on the patient, the tissue and the clinical setting.